Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Treatment duration for patients with drug-resistant tuberculosis, United States.

Winston CA, Mitruka K.

Emerg Infect Dis. 2012 Jul;18(7):1201-2. doi: 10.3201/eid1807.120261. No abstract available.

2.

Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.

Sun Z, Zhang J, Song H, Zhang X, Li Y, Tian M, Liu Y, Zhao Y, Li C.

Int J Tuberc Lung Dis. 2010 Nov;14(11):1436-41, i.

PMID:
20937184
3.

[Reasons for drug-resistant tuberculosis emergence].

Tu DH.

Zhonghua Jie He He Hu Xi Za Zhi. 2007 Jun;30(6):403-5. Chinese. No abstract available.

PMID:
17673006
4.

Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?

Velayati AA, Farnia P, Masjedi MR, Hoffner S.

Int J Tuberc Lung Dis. 2013 Jun;17(6):849-50. doi: 10.5588/ijtld.13.0066. No abstract available.

PMID:
23676176
5.

Isoniazid-resistant tuberculous meningitis, United States, 1993-2005.

Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP.

Emerg Infect Dis. 2011 Mar;17(3):539-42. doi: 10.3201/eid1703.101715.

6.

Resistance patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Nairobi.

Ndung'u PW, Kariuki S, Ng'ang'a Z, Revathi G.

J Infect Dev Ctries. 2012 Jan 12;6(1):33-9.

7.

High prevalence of multidrug-resistant tuberculosis in Zunyi, Guizhou Province of China.

Chen L, Li N, Liu M, Zhang J, Zhang H.

J Antimicrob Chemother. 2011 Oct;66(10):2435-7. doi: 10.1093/jac/dkr319. Epub 2011 Jul 26. No abstract available.

PMID:
21795258
8.

[Trends in tuberculosis treatment duration].

Veziris N, Aubry A, Truffot-Pernot C.

Presse Med. 2006 Nov;35(11 Pt 2):1758-64. Review. French.

PMID:
17086138
9.
10.

Cutting costs on mono-resistant tuberculosis diagnosis could eventually end up being more expensive.

Rouzaud F, Robledo J.

Indian J Med Microbiol. 2010 Oct-Dec;28(4):412-3. doi: 10.4103/0255-0857.71808. No abstract available.

11.
12.

[Clinical value of microchip technology in determination of drug resistance of Mycobacterium tuberculosis].

Vasil'eva IA, Chernousova LN, Zasedatelev AS, Sobolev AIu, Mikhaĭlovich VM.

Probl Tuberk. 2002;(6):21-4. Russian.

PMID:
12227044
13.

Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.

Khan MY, Kinsara AJ, Osoba AO, Wali S, Samman Y, Memish Z.

Int J Antimicrob Agents. 2001 May;17(5):415-8.

PMID:
11337231
14.

Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Park SK, Kim JH, Kang H, Cho JS, Smego RA Jr.

Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001. Epub 2008 Sep 2.

15.

[Bactericidal therapy in patients with tuberculosis].

Krasnov VA, Ursov IG.

Probl Tuberk Bolezn Legk. 2004;(3):21-6. Russian. No abstract available.

PMID:
15338895
16.

Drug-resistant tuberculosis in the Philippines.

Rivera AB, Tupasi TE, Balagtas ED, Cardano RC, Baello BQ, Quelapio ID, Villa LA, Pascual LG, Co VM, Mantala MJ.

Int J Tuberc Lung Dis. 1999 Jul;3(7):639. No abstract available.

PMID:
10423229
17.

[Characteristics of Mycobacterium tuberculosis strains circulating in Pskov region].

Viazovaia AA, Zhuravlev VIu, Mokrousov IV, Otten TF, Pavlova EP, Krishevich VV, Vishnevskiĭ BI, Narvskaia OV.

Zh Mikrobiol Epidemiol Immunobiol. 2011 Nov-Dec;(6):27-31. Russian.

PMID:
22308723
18.
19.

Multidrug-resistant Mycobacterium tuberculosis, Southwestern Colombia.

Ferro BE, Nieto LM, Rozo JC, Forero L, van Soolingen D.

Emerg Infect Dis. 2011 Jul;17(7):1259-62. doi: 10.3201/eid1707.101797.

20.

Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.

Liu Z, Shilkret KL, Finelli L.

Int J Epidemiol. 1998 Feb;27(1):121-6.

PMID:
9563705

Supplemental Content

Support Center